Roche
Corporate/Government Newsroom
As a research-focused healthcare company, Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals - from early detection and prevention of diseases to diagnosis, treatment, and treatment monitoring. Doing now what patients need next. Source
Actions
Media Outlet details
| Scope | International |
|---|---|
| Language | English |
| Country | Switzerland |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
Recent Articles
Search ArticlesNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dear Investor, Please find attached a press release from our partner Nurix Therapeutics: https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-first-patient-enrolled/ Do not hesitate to contact us for any further questions.
CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)
Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections1-3 By continuously delivering medicine into the eye through the Contivue® refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics.
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Compound Milestone Regulatory Gazyva/Gazyvaro Several autoimmune diseases FDA grants Priority Review for Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy (pMN) The Priority Review decision is based on results from the phase III MAJESTY study, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus.
Reminder: Invitation to Roche’s Half Year Results 2026 Presentation
Roche will publish its Half Year Results of 2026 prior to the opening of the Swiss Stock Exchange on Thursday, 23 July 2026.
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus1 If approved, Gazyva/Gazyvaro will be the first FDA-approved therapy for primary membranous nephropathy (pMN), following global approvals in lupus nephritis and ongoing regulatory filings in lupus and idiopathic nephrotic syndrome pMN is a chronic autoimmune disease with no FDA or EMA approved therapies to date; when...
Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis
The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types.
Roche receives CE Mark for blood test to identify tuberculosis infection
The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets. Performed on Roche’s industry-leading and widely available cobas immunoassay systems, the test enables laboratories to meet growing tuberculosis infection testing needs by reducing reliance on manual workflows through automation and digital solutions.
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa BrainshuttleTM AD study and design of Phase III PrevenTRON study in preclinical Alzheimer’s New data on Roche’s CE mark Elecsys pTau217 blood test will be presented on its use for Alzheimer's diagnosis in both primary and secondary care Basel, 7 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it will present new data from its Alzheimer’s disease...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population Data will be submitted to health authorities and presented at an...